

Supplementary table 1. Clinical characteristics of the patients included in the study diagnosed with epithelial ovarian cancer.

Variable median (min-max)	Studied population (n=23)		Total Population (n = 68)	
	Experimental arm Control (n=13)	Experimental arm Bevacizumab (n=10)	Experimental arm Control (n=33)	Experimental arm Bevacizumab (n=35)
Age	64 (41-82)	65(42-74)	57 (36–82)	63 (33–78)
ECOG PS, n (%)				
0	4 (31)	2 (20)	5 (15)	8 (23)
1	7 (54)	8 (80)	21 (64)	24 (69)
2	2 (15)	1 (10)	7 (21)	3 (9)
Origin of cancer, n (%)				
Ovary	8 (62)	9 (90)	25 (76)	31 (89)
Primary peritoneal	4 (31)	1 (10)	7 (21)	4 (11)
Fallopian tube	1 (7)	0	1 (3)	0
FIGO stage, n (%)				
IIIC	8 (62)	9 (90)	22 (67)	23 (66)
IV	5 (38)	1 (10)	11 (33)	12 (34)
Histological subtype, n (%)				
Serous	10 (77)	9 (90)	26 (79)	27 (77)
Adenocarcinoma NOS	2 (15)	1 (10)	5 (15)	7 (20)
Endometrioid/other	1(8)	-	2 (6)	1 (3)
Histological grade, n (%)				
Grade 3 (poorly differentiated)	12 (92)	10 (100)	32 (97)	35 (100)